- Home
- HRL vs QGEN Comparison
HRL vs QGEN Comparison
Compare HRL & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HRL | QGEN |
|---|---|---|
| Founded | 1891 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Meat/Poultry/Fish | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8B | 10.2B |
| IPO Year | 1994 | 1998 |
Fundamental Metrics
Financial Performance| Metric | HRL | QGEN |
|---|---|---|
| Price | $20.36 | $34.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | $26.50 | ★ $45.76 |
| AVG Volume (30 Days) | ★ 4.1M | 2.3M |
| Earning Date | 05-28-2026 | 05-06-2026 |
| Dividend Yield | 5.61% | ★ 7.17% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $12,106,160,000.00 | N/A |
| Revenue This Year | $2.66 | $8.18 |
| Revenue Next Year | $1.62 | $5.71 |
| P/E Ratio | $61.71 | ★ $24.01 |
| Revenue Growth | ★ 1.55 | N/A |
| 52 Week Low | $19.72 | $32.53 |
| 52 Week High | $31.43 | $57.82 |
Technical Indicators
Market Signals| Indicator | HRL | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 42.24 | 42.23 |
| Support Level | $20.32 | $33.17 |
| Resistance Level | $24.62 | $48.53 |
| Average True Range (ATR) | 0.55 | 0.82 |
| MACD | 0.01 | 0.25 |
| Stochastic Oscillator | 33.77 | 83.98 |
Price Performance
Historical ComparisonAbout HRL Hormel Foods Corporation
Historically meat-focused, Hormel Foods broadened its lineup to include other protein offerings and became a branded food company. The firm sells its wares through multiple channels, including US retail (61.6% of fiscal 2025 sales), US foodservice (32.6%), and international (5.9%). By product, 73% of fiscal 2025 sales were from perishable food and 27% from shelf-stable. Major brands include Hormel, Spam, Jennie-O, Columbus, Applegate, Planters, and Skippy. Many of these hold the number one or two market share in their respective categories.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).